Investors and Partnering 2017-10-28T10:24:09+00:00

Investors and partnering

ADCendo has secured funding for its early preclinical activities related to lead compound selection, pharmacology and preliminary tox studies, and will initiate discussions with potential investors regarding the funding needed for scaling up, IND enabling tox, and preparation for and making phase 1/phase 2 studies.

Further, the company will continue discussions with pharma companies, to explore potential collaboration opportunities for its projects.